The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | AKATSUKI study: emicizumab & immune tolerance induction in hemophilia A with factor VIII inhibitors
In this video, Tadashi Matsushita, MD, Nagoya University Hospital, Nagoya, Japan, briefly comments on the AKATSUKI study (jRCTs041200037), a Phase IV trial investigating the safety of emicizumab and immune tolerance induction (ITI) in patients with hemophilia A and factor VIII inhibitors. At the 96-week interim analysis, there are no concerns about the safety of this combination. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
What is the so-called AKATSUKI study performed in Japan? This study was introduced by Chugai Pharmaceutical, which is looking at the safety of the patient with inhibitors and undergoing immune tolerance induction. During the immune tolerance induction, we usually use the normal factor VIII concentrate to stop the bleeding. Except for the regular concentrate, we just introduce the emicizumab to control the bleeding...
What is the so-called AKATSUKI study performed in Japan? This study was introduced by Chugai Pharmaceutical, which is looking at the safety of the patient with inhibitors and undergoing immune tolerance induction. During the immune tolerance induction, we usually use the normal factor VIII concentrate to stop the bleeding. Except for the regular concentrate, we just introduce the emicizumab to control the bleeding. However, during some concerns about the thrombogenicity of this emicizumab, which was just said from the previous clinical trials, we just want to check the safety of the emicizumab and combination of emicizumab and ITI for patients with hemophilia. And currently, there’s no concern about safety, and most patients just develop the tolerance after the ITI trials.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Pfizer: Consultancy; Sysmex: Honoraria; CSL: Honoraria; Sanofi: Honoraria; Novo Nordisk: Consultancy, Honoraria, Research Funding; Chugai: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria; KM Biologics: Honoraria; JB Pharma: Honoraria; Takeda: Consultancy, Honoraria.
